CDC20 and cancer: While CP5V demonstrates a robust ability in degrading Cdc20, altering cyclin B levels, inducing mitotic arrest and promoting cancer cell death, the working concentration at 2 μM for CP5V still needs to be improved, and there are several strategies to improve the potency of anti-Cdc20 PROTAC.